{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:56:57Z","timestamp":1791280617567,"version":"4.1.0"},"reference-count":10,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T00:00:00Z","timestamp":1493078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T00:00:00Z","timestamp":1493078400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006314","name":"Biogen Idec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006314","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008271","name":"LEO Pharma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The Multinational Assessment of Psoriasis and Psoriatic Arthritis (\n                      <jats:styled-content style=\"fixed-case\">MAPP<\/jats:styled-content>\n                      ) survey data were not analysed to account for cultural and healthcare system differences across European countries (\n                      <jats:styled-content style=\"fixed-case\">EC<\/jats:styled-content>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To utilize\n                      <jats:styled-content style=\"fixed-case\">MAPP<\/jats:styled-content>\n                      data to characterize psoriasis in Spanish patients, including severity assessment and Dermatology Life Quality Index (\n                      <jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The MAPP survey was conducted between June and August 2012. This analysis included 1700 patients with self\u2010reported psoriasis (without psoriatic arthritis) from France (\n                      <jats:italic>n<\/jats:italic>\n                      = 349), Germany (\n                      <jats:italic>n<\/jats:italic>\n                      = 311), Italy (\n                      <jats:italic>n<\/jats:italic>\n                      = 359), Spain (\n                      <jats:italic>n<\/jats:italic>\n                      = 354) and the United Kingdom (\n                      <jats:italic>n<\/jats:italic>\n                      = 327).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients from Spain vs. other\n                      <jats:styled-content style=\"fixed-case\">EC<\/jats:styled-content>\n                      self\u2010reported higher mean body mass index (26.9 vs. 25.6,\n                      <jats:italic>P<\/jats:italic>\n                      \u2264 0.001), lower prevalence of depression (6% vs. 12%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.002) and higher mean self\u2010perceived psoriasis severity at its worst (5.92 vs. 5.33,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001) despite lower estimated body\u2010surface\u2010area involvement. Overall, patients from Spain vs. other\n                      <jats:styled-content style=\"fixed-case\">EC<\/jats:styled-content>\n                      had lower mean global\n                      <jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content>\n                      scores (4.70 vs. 6.06,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.001) and lower mean scores for each\n                      <jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content>\n                      dimension [all\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001, except leisure (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.002), treatment (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.002), and work and school (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.005)]. Higher\n                      <jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content>\n                      values were inversely associated with age and directly correlated with perceived severity. Palmoplantar, nail and scalp psoriasis were reported less frequently in Spanish patients (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.026) and were associated with higher\n                      <jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content>\n                      values (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.01). Spanish patients were more likely to have seen multiple healthcare providers (\n                      <jats:styled-content style=\"fixed-case\">HCP<\/jats:styled-content>\n                      s;\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001) and achieve therapeutic goals (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001), but current treatments were similar to patients in other\n                      <jats:styled-content style=\"fixed-case\">EC<\/jats:styled-content>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      In the\n                      <jats:styled-content style=\"fixed-case\">MAPP<\/jats:styled-content>\n                      survey, Spanish patients differed from other\n                      <jats:styled-content style=\"fixed-case\">EC<\/jats:styled-content>\n                      in several characteristics, including comorbidities, extent and distribution of psoriasis lesions, perception of severity and impact on quality of life. Their perception of psoriasis severity was higher despite a lower estimated extent, and\n                      <jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content>\n                      scores were significantly lower. Spanish patients had more\n                      <jats:styled-content style=\"fixed-case\">HCP<\/jats:styled-content>\n                      visits and a higher rate of therapeutic goal achievement. These differences might be attributed to cultural factors, phenotypical variation and differences in\n                      <jats:styled-content style=\"fixed-case\">HCP<\/jats:styled-content>\n                      access.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.14195","type":"journal-article","created":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T03:44:02Z","timestamp":1488944642000},"page":"1176-1182","source":"Crossref","is-referenced-by-count":13,"title":["A European subset analysis from the population\u2010based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country\u2010specific features: results from psoriasis patients in Spain"],"prefix":"10.1111","volume":"31","author":[{"given":"L.","family":"Puig","sequence":"first","affiliation":[{"name":"Hospital de la Santa Creu i Sant Pau Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.C.M.","family":"van de Kerkhof","sequence":"additional","affiliation":[{"name":"Radboud University Nijmegen Medical Centre Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Reich","sequence":"additional","affiliation":[{"name":"Sclderm Research Institute and Dermatologikum Hamburg Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Bachelez","sequence":"additional","affiliation":[{"name":"Department of Dermatology APHP Saint\u2010Louis Hospital Sorbonne Paris Cit\u00e9 Universit\u00e9 Paris Diderot Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Barker","sequence":"additional","affiliation":[{"name":"Division of Genetics and Molecular Medicine St. John's Institute of Dermatology King's College London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Girolomoni","sequence":"additional","affiliation":[{"name":"University of Verona Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Dermatology Paul Sabatier University and Larrey Hospital Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,4,25]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.12.018"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03563.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23621.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.2.239"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700875"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.354"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12294"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12465"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13157"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.14195","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14195","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.14195","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/chorus\/v1\/articles\/10.1111%2Fjdv.14195","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:41:50Z","timestamp":1791279710000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.14195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,25]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1111\/jdv.14195"],"URL":"https:\/\/doi.org\/10.1111\/jdv.14195","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,25]]}}}